Pfizer Maneuvers to Snare AstraZeneca as World Waits for U.S. Jobs Data
AstraZeneca investors appear underwhelmed after the first Pfizer sweetener to an indicative offer initially proposed in early January.
Global indices are mixed ahead of the U.S. non-farm payrolls report for April as many centers return to work after the May Day public holiday. AstraZeneca investors appear under-whelmed after the first Pfizer sweetener to an indicative offer initially proposed in early January. The Viagra maker is now offering about $106 billion for the British drugs group¿s stock and is lobbying U.K. politicians including PM Cameron furiously to win their approval.
